Simulations Plus, Inc. (NASDAQ:SLP) Shares Bought by US Bancorp DE

US Bancorp DE lifted its stake in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 37.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,974 shares of the technology company’s stock after purchasing an additional 1,343 shares during the period. US Bancorp DE’s holdings in Simulations Plus were worth $159,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the company. nVerses Capital LLC lifted its position in shares of Simulations Plus by 1,100.0% during the 3rd quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock worth $38,000 after purchasing an additional 1,100 shares during the last quarter. EntryPoint Capital LLC purchased a new position in shares of Simulations Plus during the 1st quarter worth approximately $57,000. Allspring Global Investments Holdings LLC purchased a new position in Simulations Plus in the 1st quarter valued at about $70,000. Los Angeles Capital Management LLC acquired a new stake in shares of Simulations Plus during the second quarter worth $206,000. Finally, Janney Montgomery Scott LLC acquired a new position in Simulations Plus during the first quarter worth approximately $208,000. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $27.66, for a total transaction of $553,200.00. Following the completion of the transaction, the director now owns 3,462,584 shares in the company, valued at approximately $95,775,073.44. This represents a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 60,750 shares of company stock valued at $1,905,655 in the last 90 days. 20.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

SLP has been the topic of several recent research reports. Stephens began coverage on shares of Simulations Plus in a report on Friday. They set an “overweight” rating and a $39.00 target price on the stock. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, November 6th. BTIG Research reduced their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. StockNews.com cut Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. Finally, KeyCorp assumed coverage on shares of Simulations Plus in a research note on Monday, July 29th. They issued an “overweight” rating and a $47.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Simulations Plus Stock Down 3.2 %

SLP stock opened at $28.77 on Friday. The firm has a 50 day moving average of $31.31 and a two-hundred day moving average of $39.04. Simulations Plus, Inc. has a 12 month low of $27.22 and a 12 month high of $51.22. The company has a market capitalization of $577.41 million, a price-to-earnings ratio of 58.72 and a beta of 0.71.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The firm had revenue of $18.70 million for the quarter, compared to analyst estimates of $19.73 million. During the same quarter in the previous year, the firm posted $0.18 EPS. The business’s revenue for the quarter was up 19.9% on a year-over-year basis. On average, research analysts expect that Simulations Plus, Inc. will post 1.12 EPS for the current fiscal year.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.